GS-5718
- Generic Name
- GS-5718
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
Phase 2
Recruiting
- Conditions
- Cutaneous Lupus Erythematosus (CLE)
- Interventions
- Drug: Edecesertib Placebo
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 33
- Registration Number
- NCT05629208
- Locations
- 🇺🇸
ARENSIA Exploratory Medicine, LLC, Phoenix, Arizona, United States
🇺🇸Center for Dermatology Clinical Research Inc., Fremont, California, United States
🇺🇸UCSD Perlman Medical Offices, La Jolla, California, United States
Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment
Phase 2
Withdrawn
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT05165771
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
Phase 1
Terminated
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 3
- Registration Number
- NCT04809623
- Locations
- 🇺🇸
Wallace Rheumatic Studies Center, LLC, Beverly Hills, California, United States
🇺🇸DJL Clinical Research, PLLC, Charlotte, North Carolina, United States
🇺🇸Clinical Research of West Florida, Inc., Clearwater, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath